Medicines QR Code – India Expands Digital Tracking to Strengthen Drug Safety Standards
Medicines QR Code – The Central Government has decided to significantly widen the use of QR code-based tracking across the pharmaceutical sector, introducing a stronger digital verification system for several critical categories of medicines. The latest regulatory changes are aimed at improving product authenticity, enhancing patient safety, and ensuring better monitoring of medicines as they move through the supply chain.
Revised Rules Expand Coverage
The decision comes after the Union Ministry of Health and Family Welfare amended the Drugs Rules, 1945. Under the revised framework, vaccines, antimicrobial medicines, anti-cancer drugs, and narcotic as well as psychotropic medicines regulated under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985, have now been brought under Schedule H2.
With this change, pharmaceutical companies manufacturing these medicines will have to print or attach a Bar Code or Quick Response (QR) Code on the product’s primary package. In situations where there is not enough space, the code can instead be placed on the secondary packaging.
Digital Verification Across the Supply Chain
The QR code will function as a digital identity for every medicine pack, allowing distributors, healthcare providers, regulators, and other authorised users to verify product details through compatible software applications.
Information stored within the code will include a unique product identification number, generic and brand names, manufacturer’s name and address, batch details, manufacturing and expiry dates, manufacturing licence number, and, wherever applicable, details relating to excipients. This system is expected to make product authentication easier at every stage of distribution.
Wider Scope Than Previous Rules
Until now, QR code labelling requirements were limited to the country’s top 300 pharmaceutical brands. The latest amendment considerably broadens the scope by extending mandatory digital identification to all vaccines, antimicrobial medicines, anti-cancer drugs, and narcotic and psychotropic medicines covered under the notified categories.
Officials believe the expanded requirement will create a more transparent pharmaceutical distribution network while helping authorities monitor medicine movement more effectively across the country.
Focus on Counterfeit Medicines and Public Health
Government officials expect the strengthened traceability framework to play an important role in reducing the circulation of counterfeit and substandard medicines. Better product verification is also expected to improve regulatory oversight and strengthen consumer confidence in pharmaceutical products.
Another major objective is to support the fight against Antimicrobial Resistance (AMR). By making it easier to identify fake or poor-quality antimicrobial medicines, authorities hope to improve treatment outcomes and reduce risks associated with ineffective drug products.
Phased Implementation Timeline
The revised provisions will be introduced in stages to allow manufacturers sufficient time for compliance. QR code requirements for vaccines, anti-cancer medicines, and narcotic and psychotropic drugs will become effective from July 1, 2027.
The implementation for antimicrobial medicines has been scheduled separately and will take effect from July 1, 2028. This phased rollout is expected to help the pharmaceutical industry gradually adopt the new packaging and digital tracking requirements without disrupting medicine supplies.
Strengthening Monitoring of Controlled Medicines
Apart from improving medicine safety, the government expects the digital tracking system to strengthen monitoring of drugs covered under the NDPS Act. Enhanced traceability will help regulators verify legitimate movement within the supply chain while supporting national efforts aimed at preventing misuse and illegal diversion of controlled pharmaceutical products.